作者:Dinakaran Murugesan、Marcel Kaiser、Karen L. White、Suzanne Norval、Jennifer Riley、Paul G. Wyatt、Susan A. Charman、Kevin D. Read、Clive Yeates、Ian H. Gilbert
DOI:10.1002/cmdc.201300177
日期:2013.9
Previously reported pyrrolones, such as TDR32570, exhibited potential as antimalarial agents; however, while these compounds have potent antimalarial activity, they suffer from poor aqueous solubility and metabolic instability. Here, further structure–activity relationship studies are described that aimed to solve the developability issues associated with this series of compounds. In particular, further
先前报道的吡咯酮,如 TDR32570,显示出作为抗疟药的潜力;然而,虽然这些化合物具有有效的抗疟活性,但它们的水溶性较差且代谢不稳定。在这里,描述了进一步的构效关系研究,旨在解决与这一系列化合物相关的可开发性问题。特别是,对吡咯酮铅的进一步修饰,包括用哌啶取代苯环并通过支架啤酒花去除潜在代谢不稳定的酯,产生了对恶性疟原虫具有改善的体外抗疟活性的衍生物K1 是一种耐氯喹和乙胺嘧啶的寄生虫菌株,其某些衍生物对寄生虫的选择性优于哺乳动物 (L6) 细胞。选择了三种代表性化合物在疟疾感染的啮齿动物模型中进行评估,最好的化合物显示出减少寄生虫血症的能力有所提高,存活率略有增加。